{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreigyuejmtc2bqif24ljt64t4ppdcr4cdp5hnlat6v6sbrmw5irfawq",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mh6oijukhrb2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiety37gujxvqagm6sejvt4nzloenkyfpy2fuie2qq3t563h24hqlm"
    },
    "mimeType": "image/jpeg",
    "size": 732228
  },
  "path": "/news/2026-03-twiceyearly-hiv-regimen-treatment-strong.html",
  "publishedAt": "2026-03-16T09:20:01.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "A new study published in The Lancet Microbe reports the first twice-yearly injectable HIV treatment regimen—combining lenacapavir, teropavimab, and zinlirvimab—has achieved high rates of viral suppression and demonstrated a favorable safety profile at 26 weeks. Led by Joe Eron, MD, a researcher with the UNC Institute for Global Health and Infectious Diseases, the findings mark a significant milestone toward what could become the first complete long-acting HIV regimen requiring dosing only twice per year.",
  "title": "Twice‑yearly injectable HIV regimen treatment demonstrates strong efficacy and safety in Phase 2 trial"
}